Neoadjuvant chemotherapy is a key component of breast cancer treatment regimens and pathologic complete response to this therapy varies among patients. This is presumably due to differences in the molecular mechanisms that underlie each tumor’s disease pathology. | The E2F4 prognostic signature predicts pathological response to neoadjuvant chemotherapy in breast cancer patients